Infant Bacterial Therapeutics AB OMXSTO:IBT_B:
SECURES PARTNERSHIP WITH RECIPHARM ADVANCED BIO FOR PRODUCTION OF DRUG SUBSTANCE
Infant Bacterial Therapeutics Secures Partnership For Production Of Drug Substance
Earlier from Infant Bacterial Therapeutics Ab Class B
- Infant Bacterial Therapeutics Q3 Operating Loss SEK 48.5 Mln
- Infant Bacterial Therapeutics AB: Quarterly Trading Report 2025 Q3
- IBT_B: FDA review of IBP-9414 progresses as losses narrow and launch preparations intensify